J&J Pulls Another Med Off the Shelves; This Time, a Schizophrenia Drug

Source: http://www.flickr.com/photos/epsos/

Johnson & Johnson (NYSE:JNJ) had another recall to announce Wednesday after it found that its Risperdal Consta, a long-acting drug purposed to treat schizophrenia, was no longer sterile.

According to Bloomberg, 5,000 vials of the drug were recalled after the company found that one lot of Risperdal Consta was contaminated with alternaria alternata, a mold found in the environment. Though no affected patients have filed complaints or complications with the drug, the company is committed to precautionary safety, and has thus ordered the removal of the vials from store shelves.

Those recalled 5,000 vials are the only ones remaining from J&J’s 70,000 originally manufactured lot that it shares with wholesalers, distributors, pharmacies, and doctors, but still — no incidents have been cited. Robyn Reed Frenze, spokeswoman for the New Brunswick, New Jersey-based company maintains that injection sites reactions are still possible, but explains, ”The risk to patients is low. We don’t want to create unnecessary concern.”